

**IN THE CLAIMS:**

**This listing of claims will replace all prior versions and listing of claims in the application.**

**Listing of the claims:**

Claims 1-10 (**cancelled**).

Claim 11 (**new**): A method for the treatment or prophylaxis of pancreatic cancer which comprises the administration to a warm-blooded animal that is in need of such treatment of synergistically effective therapeutic amounts of

a Src inhibitor selected from 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline and 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline and pharmaceutically-acceptable acid-addition salts thereof; and gemcitabine.

Claim 12 (**new**): A method for the treatment or prophylaxis of pancreatic cancer which comprises the administration to a warm-blooded animal that is in need of such treatment of synergistically effective therapeutic amounts of the Src inhibitor 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline, or a pharmaceutically-acceptable acid-addition salt thereof, and gemcitabine.

Claim 13 (**new**): A method for the treatment or prophylaxis of pancreatic cancer which comprises the administration to a warm-blooded animal that is in need of such treatment of synergistically effective therapeutic amounts of the Src inhibitor 4-(6-chloro-2,3-methylenedioxyanilino)-7-(2-piperidinoethoxy)-5-tetrahydropyran-4-yloxyquinazoline, or a pharmaceutically-acceptable acid-addition salt thereof, and gemcitabine.